Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure [PDF]
, 2002 Background: The cytotoxic treatment of patients suffering from advanced or metastatic cancer undergoing hemodialysis due to chronic renal failure still remains a problem, since for those patients pharmacokinetic and pharmacodynamic data on most cytotoxic
Stemmler, J. +4 more
core +1 more source
Irinotecan (CPT-11) Treatment Induces Mild Gonadotoxicity
Frontiers in Reproductive Health, 2022 Background:Gonadal toxicity following chemotherapy is an important issue among the population of young cancer survivors. The inhibitor of DNA topoisomerase I, irinotecan (CPT-11), is widely used for several cancer types.
Mattan Levi +4 more
doaj +1 more source
Successful Treatment of Irinotecan-Induced Muscle Twitching: A Case Report
Clinical Medicine Insights: Case Reports, 2023 Irinotecan, a topoisomerase I inhibitor, is commonly used in the treatment of advanced colorectal cancer. Its adverse effects include delay diarrhea, severe myelosuppression, and cholinergic-like symptoms.
Yu-Ting Shun +3 more
doaj +1 more source
UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). [PDF]
Br J Clin PharmacolAbstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Chauhan D +24 more
europepmc +2 more sources
Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses [PDF]
, 2012 Background: A Phase I dose escalation first in man study assessed maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended Phase II dose of TP300, a water soluble prodrug of the Topo-1 inhibitor TP3076, and active metabolite, TP3011.
Hartley, J.A. +47 more
core +2 more sources
Monitoring of Irinotecan in Human Plasma: Sensitive Fluorescent Nanogels by Molecular Imprinting [PDF]
, 2019 A series of fluorescent molecularly imprinted nanogels to detect irinotecan (CPT11) were prepared and characterized. A set of amino acids and napthalimide polymerisable derivatives allowed to obtain polymers as soluble fluorescent nanoparticles by high ...
Cristina, Forzato +9 more
core +1 more source
Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer. [PDF]
, 2017 Acquired drug resistance to the chemotherapeutic drug irinotecan (the active metabolite of which is SN-38) is one of the significant obstacles in the treatment of advanced colorectal cancer (CRC).
Chu, CM +7 more
core +1 more source
Pharmaceuticals, 2020 Irinotecan, an anticancer drug, induces diarrhea and intestinal inflammation, resulting in an increase in the cost of care and in treatment delays.
Daniely V. S. Costa +12 more
doaj +1 more source
Circulating tumour DNA to guide rechallenge with cetuximab plus irinotecan in RAS/BRAF wild-type metastatic colorectal cancer: A nonrandomised clinical trial. [PDF]
Clin Transl MedFor patients with refractory mCRC and preserved RAS/BRAF wild‐type status, ctDNA‐guided rechallenge of cetuximab combined with irinotecan represents a viable therapeutic avenue, offering durable disease control without compromising tolerability. Our findings underscore that optimising the screening time interval is crucial for maximising therapeutic ...
Wang DS +8 more
europepmc +2 more sources
Effect of echinacoside as a palliative for irinotecan-induced intestinal mucositis
Интегративная физиология, 2023 Irinotecan, an anticancer drug, causes severe delayed diarrhea due to its active metabolite, SN-38, which damages the intestinal mucosa. This diarrhea may lead to the discontinuation of anticancer therapy in clinical practice.
Хикару Оцуки +4 more
doaj +1 more source